Skip to main content

Advertisement

Table 2 Comparison of baseline characteristics between cure of the ulcerative lesions group and not

From: Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Variables Cure of the ulcerative lesions (n = 28) Not (n = 43) *P value
Male, n (%) 10 (35.7%) 12 (27.9%) 0.6011
Age (years) 40.2 ± 12.3 38.3 ± 14.6 0.2659
Disease duration (entero-BD, months) 49.6 ± 64.1 41.9 ± 45.6 0.8923
Multiple ulceration, n (%) 7/28 (25.0%) 17/43 (39.5%) 0.3048
History of relapse, n (%) 16/28 (57.1%) 24/43 (55.8%) 1.0000
History of perforation, n (%) 7/28 (25%) 3/43 (6.98%) 0.0425*
History of surgery, n (%) 5/28 (17.9%) 3/43 (6.98%) 0.2495
Concomitant CS use, n (%) 15/28 (53.6%) 27/43 (62.8%) 0.4686
Concomitant CS dose (mg/day) 14.5 ± 20.5 15.8 ± 19.2 0.5661
Concomitant colchicine use, n (%) 7/28 (25%) 23/43 (53.5%) 0.0265*
Concomitant drug use, n (%) (MTX, MS/SSZ, AZ) 26/28 (92.9%) 34/43 (79.1%) 0.1812
Concomitant MTX use, n (%) 21/28 (75%) 20/43 (46.5%) 0.0265*
TNF-i use, n (%) 25/28 (89.3%) 24/43 (55.8%) 0.0036*
DAIBD 67.3 ± 31.0 73.5 ± 36.7 0.6332
  1. Plus-minus values are means ± standard deviation. *P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease